F3Logic’s Vertex Pharmaceuticals VRTX Stock Holding History

F3Logic’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-734	Closed	-$200	–	428
2020 Q3	$200	Sell	734 -153	-17%	-$42.2K	0.01%	440
2020 Q2	$261K	Buy	+887	New	+$240K	0.05%	145

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

F3Logic's VRTX Position: Q4 2020 in Review

F3Logic sold out of Vertex Pharmaceuticals (VRTX) in Q4 2020, closing a stake of 734 shares — an estimated $200 sold.

F3Logic first reported a position in VRTX in Q2 2020 and held it in 2 quarters. The position peaked at $261K in Q2 2020. 970 funds tracked by Wall St. Rank hold VRTX as of Q4 2020.

F3Logic reported no remaining Vertex Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
F3Logic sold 734 Vertex Pharmaceuticals shares in Q4 2020, an estimated $200.
F3Logic first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 2 quarters.
F3Logic's Vertex Pharmaceuticals position peaked at $261K in Q2 2020.
970 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2020.

Based on F3Logic's 13F filing for Q4 2020, filed 12 Feb 2021.